Gsk (GLAXF) Short-term Investments (2009 - 2026)

Gsk's Short-term Investments history runs 18 years deep, the most recent figure standing at -$258.9 million for Q1 2026.

• In Q1 2026, Short-term Investments fell 316.33% year-over-year to -$258.9 million; the TTM figure through Mar 2026 stood at -$258.9 million (down 316.33% YoY), while the FY2025 annual figure was $159.5 million, up 14.5% from the prior year.
• Short-term Investments was -$258.9 million for Q1 2026 at Gsk, down from $161.0 million in the prior quarter.
• In the past five years, Short-term Investments ranged from a high of $4.8 billion in Q4 2022 to a low of -$383.0 million in Q3 2022.
• Historically, Short-term Investments has averaged $480.0 million across 5 years, with a median of $139.9 million in 2024.
• The sharpest annual moves came in 2022 and 2023: Short-term Investments tumbled 555.48% in 2022, then jumped 639.2% in 2023.
• A 5-year view of Short-term Investments shows it stood at $4.8 billion in 2022, then slumped by 42.94% to $2.7 billion in 2023, then slumped by 94.89% to $139.9 million in 2024, then grew by 15.05% to $161.0 million in 2025, then slumped by 260.83% to -$258.9 million in 2026.
• The last three Short-term Investments figures came in at -$258.9 million (Q1 2026), $161.0 million (Q4 2025), and -$152.5 million (Q3 2025), per Business Quant data.